Servicios Personalizados
Revista
Articulo
Indicadores
Citado por SciELO
Links relacionados
Similares en SciELO
Compartir
Insuficiencia cardíaca
versión On-line ISSN 1852-3862
Resumen
FONTECHA, María Belén; ANADON, María del Rosario; MAZZEI, Juan Antonio y FREYA FUNDIA, Ariela. Avances en la genética de la hipertensión arterial pulmonar. Insuf. card. [online]. 2020, vol.15, n.1, pp.10-18. ISSN 1852-3862.
Pulmonary arterial hypertension (PAH) is a serious and incurable cardiopulmonary disorder with significant morbidity and mortality. It is characterized by the occlusion and remodeling of the pulmonary arterioles, progressive respiratory failure, right ventricular dysfunction, heart failure and premature death. PAH can occur in different forms, including idiopathic (IPAH) in absence of a known cause and hereditary (HPAH) if related to a genetic alteration or if there is familial aggregation. Besides these forms, there are other causes of PAH associated with various medical conditions (drugs, toxins, HIV infection, etc.). Despite recent advances in PAH, it remains a challenging disease to both diagnosis and management. Research about the genetic basis of PAH has contributed significantly to improve the understanding of this condition. The most common genetic alterations associated with PAH are inactivating mutations in the gene encoding a bone morphogenetic protein receptor type 2 (BMPR2). Patients with BMPR2 mutations present PAH at a younger age with more severe disease, and have an increased risk of death or transplantation, than those without mutations. Recent advances have led to the discovery of new genes related to PAH, such as ACVRL1 (activin A receptor like type 1), ENG (endoglin), CAV1 (caveolin-1), KCNK3 (potassium channel subfamily K, member 3), among others. In this review, we summarize the knowledge about rare and common genetic variants that underlie PAH development and prognosis. Additionally, we outline the importance of implementing genetic counseling and testing in specialized pulmonary hypertension centers. Understanding the genetics of PAH will provide new insights into the mechanisms underlying its pathobiology potentially useful for developing new therapeutic strategies within the scope of a personalized medicine.
Palabras clave : Pulmonary arterial hypertension; BMPR2 gene; Mutations; Genetics; Genomics.